The role of EphA2 in tumors is complex as it may be either tumor suppressive or tumor promoting depending on the binding of different EFN ligands which influence both classical tyrosine dependent signaling as well as non-canonical activation as illustrated in multiple tumor types, e.g., glioblastoma, breast cancer, malignant melanoma, prostate cancer and ovarian carcinoma [20,21,22,23,37,38,39,40,41,42,43]. Here, EPHA2 is linked to neoplasm.